Danno Pharmaceutical-B (06872) plans to repurchase H shares of no more than 50 million yuan

Zhitong Finance App News, Danno Pharmaceutical-B (06872) announced that since the current market price of H shares does not fully reflect the company's intrinsic value and business development prospects, the board of directors plans to exercise its powers in accordance with the repurchase authorization. With the approval of the board of directors, the company will repurchase H shares on the open market from time to time according to market conditions, with a total repurchase amount not exceeding RMB 50 million. The company will use its own funds to disburse the funds required for the H share repurchase plan.

The board of directors believes that the repurchase of H shares in the current market situation will show the company's confidence in its own business outlook and prospects, and will ultimately benefit the company and create value for shareholders. Implementing the H share repurchase plan will not have a significant adverse impact on the company's financial position or its day-to-day business processes. Therefore, the board of directors believes that implementing the H share repurchase plan is in the overall interests of the company and shareholders.